Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)
J. Clin. Oncol 2021 Jan 06;[EPub Ahead of Print], A Gajjar, GW Robinson, KS Smith, T Lin, TE Merchant, M Chintagumpala, A Mahajan, J Su, E Bouffet, U Bartels, T Schechter, T Hassall, T Robertson, W Nicholls, S Gururangan, K Schroeder, M Sullivan, G Wheeler, JR Hansford, SJ Kellie, G McCowage, R Cohn, MJ Fisher, MJ Krasin, CF Stewart, A Broniscer, I Buchhalter, RG Tatevossian, BA Orr, G Neale, P Klimo, F Boop, A Srinivasan, SM Pfister, RJ Gilbertson, A Onar-Thomas, DW Ellison, PA NorthcottFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.